A tertiary care center's cost-effective examination of different antibiotic regimen used to treat pneumonia
Abstract
Objective: To evaluate the cost-effectiveness of different antibiotics in treating adult patients with community-acquired pneumonia (CAP). Methodology: This retrospective study analyzed 100 case sheets of CAP patients admitted to the Medical Centre between January 2024 and December 2024. The case sheets contained details on various antibiotics administered both orally and intravenously. The most commonly used antibiotics included azithromycin, ampicillin-sulbactam, levofloxacin, cefuroxime, and amoxicillin-clavulanate. Intravenous antibiotics showed a more significant improvement in patient outcomes compared to oral antibiotics. To assess cost-effectiveness, we conducted a pharmacoeconomic analysis and applied a cost-effectiveness evaluation of these antibiotics. The cost-effectiveness coefficient was determined by dividing the monthly number of asymptomatic days by the cost of antibiotics.Results: The cost-effectiveness coefficient ratio indicated that continuous intravenous antibiotic therapy is significantly more expensive than switch therapy.Conclusion: When clinically appropriate, transitioning from intravenous to oral antibiotics at the right time can reduce unnecessary healthcare costs while maintaining effective treatment outcomes.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.